Syngene International Limited is one of Asia’s leading contract research, development, and manufacturing organizations (CRDMO), providing integrated scientific services to global pharmaceutical, biotechnology, animal health, consumer health, and specialty chemical companies. Established in 1993 as a subsidiary of Biocon Limited, the company supports customers across the entire drug discovery and development lifecycle, from early-stage research to commercial manufacturing. Syngene offers expertise in medicinal chemistry, biology, toxicology, biologics, analytical development, clinical manufacturing, and commercial-scale production. The company operates world-class research campuses and manufacturing facilities that comply with international regulatory standards, serving many of the world’s leading pharmaceutical innovators. Through strategic collaborations, advanced technologies, and scientific excellence, Syngene enables customers to accelerate innovation while improving development efficiency. Its continued investment in infrastructure, digital technologies, and biologics manufacturing has positioned the company among the world’s most respected CRDMOs and a key partner in global pharmaceutical innovation.
NSE: SYNGENE | BSE: 539268
Bengaluru, Karnataka, India
~8,000 employees
